Adaptive Biotechnologies Co. (NASDAQ:ADPT) Insider Sells $144,582.40 in Stock

Last updated on Wednesday, July 21, 2021 | 2021 MarketBeat

Adaptive Biotechnologies Co. (NASDAQ:ADPT) insider Harlan S. Robins sold 3,895 shares of the business's stock in a transaction that occurred on Monday, July 19th. The shares were sold at an average price of $37.12, for a total value of $144,582.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of ADPT stock traded up $0.19 during trading hours on Wednesday, reaching $38.18. 397,404 shares of the company's stock were exchanged, compared to its average volume of 916,696. Adaptive Biotechnologies Co. has a fifty-two week low of $30.41 and a fifty-two week high of $71.25. The company has a market capitalization of $5.36 billion, a PE ratio of -33.20 and a beta of 0.28. The business's fifty day simple moving average is $37.75.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Tuesday, May 4th. The company reported ($0.29) EPS for the quarter, topping analysts' consensus estimates of ($0.41) by $0.12. The company had revenue of $38.44 million during the quarter, compared to analyst estimates of $28.53 million. Adaptive Biotechnologies had a negative return on equity of 22.42% and a negative net margin of 134.12%. Research analysts forecast that Adaptive Biotechnologies Co. will post -1.55 earnings per share for the current year.

ADPT has been the subject of several analyst reports. Zacks Investment Research lowered Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Tuesday. Morgan Stanley reduced their target price on Adaptive Biotechnologies from $60.00 to $55.00 and set an "equal weight" rating for the company in a report on Friday, May 7th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of "Buy" and a consensus target price of $59.20.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Arizona State Retirement System increased its position in shares of Adaptive Biotechnologies by 1.1% during the first quarter. Arizona State Retirement System now owns 25,880 shares of the company's stock valued at $1,042,000 after purchasing an additional 282 shares during the period. Xponance Inc. increased its position in shares of Adaptive Biotechnologies by 5.0% during the first quarter. Xponance Inc. now owns 8,168 shares of the company's stock valued at $329,000 after purchasing an additional 390 shares during the period. Alliancebernstein L.P. increased its position in shares of Adaptive Biotechnologies by 1.0% during the first quarter. Alliancebernstein L.P. now owns 43,063 shares of the company's stock valued at $1,734,000 after purchasing an additional 412 shares during the period. Sowell Financial Services LLC increased its position in shares of Adaptive Biotechnologies by 138.3% during the first quarter. Sowell Financial Services LLC now owns 822 shares of the company's stock valued at $30,000 after purchasing an additional 477 shares during the period. Finally, CIBC Asset Management Inc increased its position in shares of Adaptive Biotechnologies by 10.7% during the first quarter. CIBC Asset Management Inc now owns 5,092 shares of the company's stock valued at $205,000 after purchasing an additional 493 shares during the period. Institutional investors and hedge funds own 80.48% of the company's stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson in September 2009 and is headquartered in Seattle, WA.

Further Reading: Dual Listing

Insider Buying and Selling by Quarter for Adaptive Biotechnologies (NASDAQ:ADPT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Why investors pay attention to retained earnings


7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future

When you say the Internet of Things (IoT) you may get different responses. I like to think of it broadly as being about connection. It’s about devices that can connect with each other, and with the internet. And this provides users with the solutions that are making our lives more convenient.

The most basic, and ubiquitous, example of an IoT device is the smartphone that many of us have with us at all times. But think about what that has led to. Home assistants, security cameras, fitness apps, and so much more are all enabled by the internet of things.

IoT took on even more importance in the pandemic as businesses had to find a way to ensure the security and viability of their networks even as their employees were scattered remotely. This created demand for edge and cloud computing solutions that are also facilitated by the internet of things.

And yes, this is just the start. The need for more and more data is powering demand for IoT solution in areas such as autonomous vehicles.

But the good news is that this is an area that is still very much in its growth phase. And that means there is no lack of companies that you can find to trade in this sector. To help you get started, we’ve put together this special presentation that highlights seven such companies and the reasons why we believe they merit adding to your portfolio.

View the "7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future".


MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.